Your browser doesn't support javascript.
loading
Congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1.
Ludwig, Leif S; Lareau, Caleb A; Bao, Erik L; Liu, Nan; Utsugisawa, Taiju; Tseng, Alex M; Myers, Samuel A; Verboon, Jeffrey M; Ulirsch, Jacob C; Luo, Wendy; Muus, Christoph; Fiorini, Claudia; Olive, Meagan E; Vockley, Christopher M; Munschauer, Mathias; Hunter, Abigail; Ogura, Hiromi; Yamamoto, Toshiyuki; Inada, Hiroko; Nakagawa, Shinichiro; Ohzono, Shuichi; Subramanian, Vidya; Chiarle, Roberto; Glader, Bertil; Carr, Steven A; Aryee, Martin J; Kundaje, Anshul; Orkin, Stuart H; Regev, Aviv; McCavit, Timothy L; Kanno, Hitoshi; Sankaran, Vijay G.
Affiliation
  • Ludwig LS; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Lareau CA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Bao EL; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.
  • Liu N; Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Utsugisawa T; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany.
  • Tseng AM; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Myers SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Verboon JM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.
  • Ulirsch JC; Department of Computer Science and.
  • Luo W; Department of Genetics, Stanford University, Stanford, CA.
  • Muus C; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Fiorini C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Olive ME; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.
  • Vockley CM; Harvard-MIT Health Sciences and Technology, Harvard Medical School, Boston, MA.
  • Munschauer M; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Hunter A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Ogura H; Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Yamamoto T; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
  • Inada H; Department of Transfusion Medicine and Cell Processing, Faculty of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
  • Nakagawa S; Department of Computer Science and.
  • Ohzono S; Department of Genetics, Stanford University, Stanford, CA.
  • Subramanian V; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.
  • Chiarle R; La Jolla Institute for Immunology, La Jolla, CA.
  • Glader B; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Carr SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Aryee MJ; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.
  • Kundaje A; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Orkin SH; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Regev A; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.
  • McCavit TL; Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, MA.
  • Kanno H; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Sankaran VG; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Blood ; 139(16): 2534-2546, 2022 04 21.
Article in En | MEDLINE | ID: mdl-35030251
ABSTRACT
Master regulators, such as the hematopoietic transcription factor (TF) GATA1, play an essential role in orchestrating lineage commitment and differentiation. However, the precise mechanisms by which such TFs regulate transcription through interactions with specific cis-regulatory elements remain incompletely understood. Here, we describe a form of congenital hemolytic anemia caused by missense mutations in an intrinsically disordered region of GATA1, with a poorly understood role in transcriptional regulation. Through integrative functional approaches, we demonstrate that these mutations perturb GATA1 transcriptional activity by partially impairing nuclear localization and selectively altering precise chromatin occupancy by GATA1. These alterations in chromatin occupancy and concordant chromatin accessibility changes alter faithful gene expression, with failure to both effectively silence and activate select genes necessary for effective terminal red cell production. We demonstrate how disease-causing mutations can reveal regulatory mechanisms that enable the faithful genomic targeting of master TFs during cellular differentiation.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: GATA1 Transcription Factor / Anemia Limits: Humans Language: En Journal: Blood Year: 2022 Type: Article Affiliation country: Morocco

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: GATA1 Transcription Factor / Anemia Limits: Humans Language: En Journal: Blood Year: 2022 Type: Article Affiliation country: Morocco